September 23, 2011 -- AstraZeneca plans to continue an emphasis on partnership in China drug development, rather than outright acquisition of China biopharmas with promising technology, according to Steve Yang, PhD, AstraZeneca vice-president and head of R&D for Asia and emerging markets. “In China, our collaboration strategy is to forge partnership with leading academic and medical institutions that already have in-depth expertise in Asia-specific diseases,” said Yang. More details....
Stock Symbol: (NYSE: AZN)
